HC Wainwright Has Pessimistic Outlook of SRTS Q2 Earnings

Key Points

• HC Wainwright has reduced its Q2 2026 earnings per share estimate for Sensus Healthcare from $0.03 to ($0.01), maintaining a "Buy" rating with a price target of $8.00.
• Institutional investors have shown interest in Sensus Healthcare, acquiring significant new stakes, with institutionals now holding 25.30% of the company's stock.
• For its most recent quarter, Sensus Healthcare reported ($0.06) earnings per share, missing the consensus estimate and generating revenue of $7.32 million, which was below expectations.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Sensus Healthcare in a research report issued on Tuesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.03. HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share.

Several other analysts have also recently commented on SRTS. Maxim Group lowered their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Lake Street Capital lowered their target price on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd.

Sensus Healthcare Trading Down 1.2%

SRTS traded down $0.04 during trading hours on Wednesday, hitting $3.31. The company's stock had a trading volume of 72,264 shares, compared to its average volume of 191,726. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $9.33. The firm has a market capitalization of $54.42 million, a PE ratio of -55.17 and a beta of 1.34. The company has a 50-day simple moving average of $4.69 and a 200 day simple moving average of $4.86.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. The business had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in shares of Sensus Healthcare during the 1st quarter valued at $26,000. JPMorgan Chase & Co. acquired a new position in shares of Sensus Healthcare during the 4th quarter valued at $27,000. Barclays PLC acquired a new position in shares of Sensus Healthcare during the 4th quarter valued at $35,000. BNP Paribas Financial Markets acquired a new position in shares of Sensus Healthcare during the 4th quarter valued at $47,000. Finally, Vise Technologies Inc. acquired a new position in shares of Sensus Healthcare during the 2nd quarter valued at $52,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.